Clostridioides difficile Infection Rates after Ceftolozane–Tazobactam and Ceftazidime–Avibactam Treatment Compared to Carbapenem Treatment: A Retrospective Single-Center Study

Introduction: Ceftolozane–tazobactam (CT) and ceftazidime–avibactam (CZA) are new beta-lactam/beta-lactamase inhibitors (BL/IBL) antibiotics. There few data regarding their impact on Clostridioides difficile infections (CDI). The objective of our study was, therefore, to determine compare the number CDI occurring after treatment with CT or CZA carbapenem (CBP). Methods: All patients who received at least one dose in hospital between 1 January 2018 31 December 2019 were included. We compared, during same period, CBPs by using a chi-square test Fischer’s exact when required. p value < 0.05 was considered as significant. Results: Among 53 receiving 42 CT, two one, respectively, developed within 90 days. Of three (3%) CDI, died 15 days his second (36 initiation CZA). 2291 CBP, 37 (1.6%) no significant difference CBP treatment. use is not associated an increased rate compared CBP.